Fresenius Kabi has delivered on long held ambitions to join the biosimilars party in the US, offering another pegfilgrastim subcutaneous injectable in a crowded market of biosimilar sponsors.
Fresenius Kabi’s Stimufend (pegfilgrastim-fpgk) “represents the first of many biosimilar products [we will] launch in the US,” the German firm has underlined, after making its foray into the US biosimilar market with its rival to Amgen’s Neulasta (pegfilgrastim) subcutaneous injectable.
In roughly six weeks, a Q-code assigned to the biosimilar for Medicare claims processing will kick in, Kabi told Generics...
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
